arrow
F

Fabian Finkelmeier

University Hospital Frankfurt
H指数:35
被引数:5,806

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Early and Late Survival Dynamics of Immunotherapy Combinations in Advanced HCC: Anchored Indirect Comparison of Atezolizumab plus Bevacizumab versus Durvalumab + Tremelimumab

晚期肝细胞癌免疫疗法联合方案的早期与晚期生存动态:阿替利珠单抗联合贝伐珠单抗与度伐利尤单抗联合特瑞普利单抗的锚定间接比较

2026-04-210
PRE
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study

安全性、药代动力学及VS-01(一种腹腔内脂质体输注)在失代偿期肝硬化、腹水及隐匿性肝性脑病患者的初步疗效:一项1b期、首次人体、开放标签、非随机化、单次及多次递增剂量研究

2026-02-170
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population

阿特珠单抗联合贝伐珠单抗与仑伐替尼对比用于巴塞罗那临床肝癌分期B期(BCLC-B)肝细胞癌(HCC)患者:一项真实世界人群研究

2025-06-090
PRE
A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab

一种用于接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者的新型预后指数

2024-12-010
PRE
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
2024-11-211
PRE
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort

阿特珠单抗/贝伐单抗和乐伐替尼治疗肝细胞癌: 欧洲真实世界队列的比较分析

2024-11-013
OAAI
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
2024-11-011
OAAI
A novel ultrasound-based algorithm for the detection of pancreatic stents placed for prophylaxis of post-ERCP pancreatitis: a prospective trial

一种基于超声的新算法,用于检测用于预防ERCP术后胰腺炎的胰腺支架: 一项前瞻性试验

2024-09-250
OAAI
A New Drying Method of Thermolabile Flexible Endoscope Channels by Laminar and Turbulent Airflow: A Prospective, Randomized-Controlled, Single-Center, Proof-of-Concept Trial

一种通过层流和湍流气流干燥热不稳定柔性内窥镜通道的新方法:一项前瞻性、随机对照、单中心、概念验证试验

2024-09-230
PRE
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort
2024-09-202
OAAI